Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen 1/2020

10.01.2020 | Originalien

Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?

Gesamtauswertung des Deutschen Kieferosteonekroseregisters

verfasst von: BA Cand. med. Dent. Niels Karberg, Prof. Dr. med. Dieter Felsenberg

Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Die erste Veröffentlichung zum Thema der Osteonekrose des Kieferknochens (ONJ, „osteonecrosis of the jaw“) erfolgte 2003. Bei Tumor- und Osteoporosepatienten werden im Zuge ihrer Grunderkrankung Bisphosphonate appliziert. Dies geschieht bei Tumorpatienten zur Risikoreduktion der Entwicklung einer Knochenmetastasierung, bei Osteoporosepatienten zur Verringerung des Frakturrisikos. Trotz der geringen Wahrscheinlichkeit werden Nebenwirkungen in Form von Nekrosen nach Interventionen am Kieferknochen häufig von den behandelnden Ärzten erwartet. Nach Auswertung der Registerdaten konnte nicht festgestellt werden, dass die Länge der Einnahme mit der Prävalenz von ONJ korreliert. Die Lokalisationen der ONJ decken sich weitestgehend mit den Ergebnissen bisheriger Studien.
Literatur
1.
Zurück zum Zitat Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117 CrossRefPubMed Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117 CrossRefPubMed
2.
Zurück zum Zitat Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534 CrossRefPubMed Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534 CrossRefPubMed
3.
Zurück zum Zitat Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (2004) Osteonekrose des Kiefers unter Bisphosphonaten. Dtsch Arztebl 101:A2203 Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (2004) Osteonekrose des Kiefers unter Bisphosphonaten. Dtsch Arztebl 101:A2203
4.
Zurück zum Zitat Freyschmidt J (1980) Knochenerkrankungen im Erwachsenenalter. Springer, Berlin CrossRef Freyschmidt J (1980) Knochenerkrankungen im Erwachsenenalter. Springer, Berlin CrossRef
5.
Zurück zum Zitat Akintoye SO, Lam T, Shi S et al (2006) Skeletal sitespecific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 38:758–768 CrossRefPubMed Akintoye SO, Lam T, Shi S et al (2006) Skeletal sitespecific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 38:758–768 CrossRefPubMed
6.
Zurück zum Zitat Stefanik D, Sann J, Lam T et al (2008) Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis 14:465–471 CrossRefPubMedPubMedCentral Stefanik D, Sann J, Lam T et al (2008) Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis 14:465–471 CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D’Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P (2006) Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 77(2):109–117 PubMed Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D’Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P (2006) Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 77(2):109–117 PubMed
8.
Zurück zum Zitat Re M, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575 CrossRef Re M, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575 CrossRef
10.
Zurück zum Zitat Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222–6230 CrossRef Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222–6230 CrossRef
11.
Zurück zum Zitat Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860 CrossRefPubMed Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860 CrossRefPubMed
12.
Zurück zum Zitat Bartl R, von Tresckow E, Bartl C (2006) Bisphosphonat Manual. Springer, Berlin, Heidelberg, New York, S 43–93. ISBN 3‑540-25362‑9 CrossRef Bartl R, von Tresckow E, Bartl C (2006) Bisphosphonat Manual. Springer, Berlin, Heidelberg, New York, S 43–93. ISBN 3‑540-25362‑9 CrossRef
13.
Zurück zum Zitat Yamaguchi A, Kubo S, Matsunaga T, Shibahara T (2018) Report by the jaw bone disease project 1: concept, diagnosis and treatment of medication-related osteonecrosis of the jaw. Shikwa Gakuho 118:165–176 Yamaguchi A, Kubo S, Matsunaga T, Shibahara T (2018) Report by the jaw bone disease project 1: concept, diagnosis and treatment of medication-related osteonecrosis of the jaw. Shikwa Gakuho 118:165–176
14.
Zurück zum Zitat Fleisch H (2002) The role of bisphosphonates in breast cancer: development of bisphosphonates. Breast Cancer Res 4(1):30–34 CrossRefPubMed Fleisch H (2002) The role of bisphosphonates in breast cancer: development of bisphosphonates. Breast Cancer Res 4(1):30–34 CrossRefPubMed
15.
Zurück zum Zitat Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001) Mutschler Arnzeimittelwirkungen, 8. Aufl. Wissenschaftliche Vertragsgesellschaft, Stuttgart, S 395–398 Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001) Mutschler Arnzeimittelwirkungen, 8. Aufl. Wissenschaftliche Vertragsgesellschaft, Stuttgart, S 395–398
16.
Zurück zum Zitat International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:1 CrossRef International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:1 CrossRef
17.
Zurück zum Zitat Aspenberg P (2006) Osteonecrosis: what does ist mean? One condition partly caused by bisphosphonates—or another one, preferably treated with them? Acta Orthop 77(5):693–694 CrossRefPubMed Aspenberg P (2006) Osteonecrosis: what does ist mean? One condition partly caused by bisphosphonates—or another one, preferably treated with them? Acta Orthop 77(5):693–694 CrossRefPubMed
18.
Zurück zum Zitat Allen MR, Ruggiero SL (2009) Higher bone matrix density exists in only subset of patients with bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67:1373–1377 CrossRefPubMed Allen MR, Ruggiero SL (2009) Higher bone matrix density exists in only subset of patients with bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67:1373–1377 CrossRefPubMed
19.
Zurück zum Zitat Sharma D, Ivanovski S, Slevin M et al (2013) Bisphosphonate-related osteonecrosis of the jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell 5:1–5 CrossRefPubMedPubMedCentral Sharma D, Ivanovski S, Slevin M et al (2013) Bisphosphonate-related osteonecrosis of the jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell 5:1–5 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Fedele S, Porter SR, D’Aiuto F et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060–1064 CrossRefPubMed Fedele S, Porter SR, D’Aiuto F et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060–1064 CrossRefPubMed
21.
Zurück zum Zitat Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433–441 CrossRefPubMed Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433–441 CrossRefPubMed
22.
Zurück zum Zitat Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544 PubMed Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544 PubMed
23.
Zurück zum Zitat Santini D, Vincenzi B, Dicuonzo G et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897 PubMed Santini D, Vincenzi B, Dicuonzo G et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897 PubMed
24.
Zurück zum Zitat Vincenzi B, Santini B, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–151 CrossRefPubMed Vincenzi B, Santini B, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–151 CrossRefPubMed
26.
Zurück zum Zitat Cartsos VM, Zhu S, Zavras A (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714.217 people. Am Dent Assoc 139:23–30 CrossRef Cartsos VM, Zhu S, Zavras A (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714.217 people. Am Dent Assoc 139:23–30 CrossRef
27.
Zurück zum Zitat Lo JC, O’Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonates exposure. Oral Maxillofac Surg 68:243–253 CrossRef Lo JC, O’Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonates exposure. Oral Maxillofac Surg 68:243–253 CrossRef
28.
Zurück zum Zitat Felsenberg D (2006) Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatment. Nat Clin Pract Endocrinol Metab 2:2662–2663 CrossRef Felsenberg D (2006) Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatment. Nat Clin Pract Endocrinol Metab 2:2662–2663 CrossRef
29.
Zurück zum Zitat Khan AA et al (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396–1402 CrossRefPubMed Khan AA et al (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396–1402 CrossRefPubMed
30.
Zurück zum Zitat Lyles KW et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809 CrossRefPubMed Lyles KW et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809 CrossRefPubMed
31.
Zurück zum Zitat Powell D, Bowler C, Roberts T et al (2012) Incidence of serious side effects with intravenous bisphosphonates: a clinical audit. QJM 105:965–971 CrossRefPubMed Powell D, Bowler C, Roberts T et al (2012) Incidence of serious side effects with intravenous bisphosphonates: a clinical audit. QJM 105:965–971 CrossRefPubMed
32.
Zurück zum Zitat Tennis P, Rothman KJ, Bohn RL et al (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810–817 CrossRefPubMed Tennis P, Rothman KJ, Bohn RL et al (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810–817 CrossRefPubMed
33.
Zurück zum Zitat Grbic JT, Landesberg R, Lin SQ et al (2008) Incidence of osteonecrosis of the jaw in women with postmenosaumal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139:32–40 CrossRefPubMed Grbic JT, Landesberg R, Lin SQ et al (2008) Incidence of osteonecrosis of the jaw in women with postmenosaumal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139:32–40 CrossRefPubMed
34.
Zurück zum Zitat Devogelaer JP, Brown JP, Burckhardt P et al (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211–1218 CrossRefPubMed Devogelaer JP, Brown JP, Burckhardt P et al (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211–1218 CrossRefPubMed
35.
Zurück zum Zitat Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia Lymphoma 49(11):2156–2162 Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia Lymphoma 49(11):2156–2162
36.
Zurück zum Zitat Klingelhoeffer Ch, Hoffmeister B (2012) Klinische Aspekte der Behandlung von Kiefernekrosen unter antiresorptiver Therapie. Osteologie 3:201–206 Klingelhoeffer Ch, Hoffmeister B (2012) Klinische Aspekte der Behandlung von Kiefernekrosen unter antiresorptiver Therapie. Osteologie 3:201–206
37.
Zurück zum Zitat Ferlito S, Puzzo S, Liardo C (2011) Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 69(6):e1–e4 CrossRefPubMed Ferlito S, Puzzo S, Liardo C (2011) Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 69(6):e1–e4 CrossRefPubMed
38.
Zurück zum Zitat Ripamonti CI et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145 CrossRefPubMed Ripamonti CI et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145 CrossRefPubMed
39.
Zurück zum Zitat Dimopoulos MA et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120 CrossRefPubMed Dimopoulos MA et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120 CrossRefPubMed
40.
Zurück zum Zitat Haidar A et al (2009) Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scand J Urol Nephrol 43:442–444 CrossRefPubMed Haidar A et al (2009) Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scand J Urol Nephrol 43:442–444 CrossRefPubMed
41.
Zurück zum Zitat Fehm T, Walter B, Wallwiener D (2010) Bisphosphonatbedingte Kieferosteonekrose. Empfehlungen zur Prävention und Therapie. Gynäkologe 43:517–520 CrossRef Fehm T, Walter B, Wallwiener D (2010) Bisphosphonatbedingte Kieferosteonekrose. Empfehlungen zur Prävention und Therapie. Gynäkologe 43:517–520 CrossRef
42.
Zurück zum Zitat Ruggiero SL, Dodson TB, Assael LA et al (2009) Task force on bisphosphonate-related osteonecrosis of the jaws. Am Assoc Oral Maxillofac Surg 69:2–12 Ruggiero SL, Dodson TB, Assael LA et al (2009) Task force on bisphosphonate-related osteonecrosis of the jaws. Am Assoc Oral Maxillofac Surg 69:2–12
43.
Zurück zum Zitat Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620–623 CrossRefPubMed Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620–623 CrossRefPubMed
44.
Zurück zum Zitat Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545 CrossRefPubMed Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545 CrossRefPubMed
45.
Zurück zum Zitat Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625–631 CrossRefPubMedPubMedCentral Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625–631 CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Chranovic BR, Albrektsson T, Wennerberg A (2015) Smoking and dental implants: a systematic review and meta-analysis. J Dent 43:487–498 CrossRef Chranovic BR, Albrektsson T, Wennerberg A (2015) Smoking and dental implants: a systematic review and meta-analysis. J Dent 43:487–498 CrossRef
47.
Zurück zum Zitat Shanbhogue VV, Mitchell DM, Rosen CJ et al (2016) Type2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol 4:159–173 CrossRefPubMed Shanbhogue VV, Mitchell DM, Rosen CJ et al (2016) Type2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol 4:159–173 CrossRefPubMed
48.
Zurück zum Zitat Yahagi K, Kolodgie FD, Lutter C et al (2017) Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arter Thromb Vasc Biol 37:191–204 CrossRef Yahagi K, Kolodgie FD, Lutter C et al (2017) Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arter Thromb Vasc Biol 37:191–204 CrossRef
49.
Zurück zum Zitat Hua Y, Bi R, Zhang Y et al (2018) Different bone sites-specific response to diabetes rat models: bone density, histology and microarchitecture. PLoS ONE 13:e205503 CrossRefPubMedPubMedCentral Hua Y, Bi R, Zhang Y et al (2018) Different bone sites-specific response to diabetes rat models: bone density, histology and microarchitecture. PLoS ONE 13:e205503 CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Vahtsevanos K et al (2009) Longitudinal cohortstudy of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362 CrossRefPubMed Vahtsevanos K et al (2009) Longitudinal cohortstudy of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362 CrossRefPubMed
51.
Zurück zum Zitat Felsenberg D, Lopez S, Gabbert T, Hoffmeister B (2012) Osteonekrose des Kiefers bei Osteoporosepatienten. Onkologie 3:207–212 Felsenberg D, Lopez S, Gabbert T, Hoffmeister B (2012) Osteonekrose des Kiefers bei Osteoporosepatienten. Onkologie 3:207–212
52.
Zurück zum Zitat Felsenberg D, Hoffmeister B, Amling M et al (2006) Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Zahnärztebl 103:3078–3080 Felsenberg D, Hoffmeister B, Amling M et al (2006) Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Zahnärztebl 103:3078–3080
53.
Zurück zum Zitat Shibahara T (2019) Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 247(2):75–86 CrossRefPubMed Shibahara T (2019) Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 247(2):75–86 CrossRefPubMed
54.
Zurück zum Zitat Vandone AM et al (2012) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 23:193–200 CrossRefPubMed Vandone AM et al (2012) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 23:193–200 CrossRefPubMed
55.
Zurück zum Zitat De Iuliis F, Taglieri L, Amoroso L, Vendittozzi S, Blasi L, Salerno G, Lanza R, Scarpa S (2014) Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Anticancer Research 34:2477–2480 De Iuliis F, Taglieri L, Amoroso L, Vendittozzi S, Blasi L, Salerno G, Lanza R, Scarpa S (2014) Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Anticancer Research 34:2477–2480
56.
Zurück zum Zitat Bramati A, Girelli S, Farina G, Chiara M et al (2015) Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 33:119–124 CrossRefPubMed Bramati A, Girelli S, Farina G, Chiara M et al (2015) Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 33:119–124 CrossRefPubMed
57.
58.
Zurück zum Zitat Gilman’s G (2011) The pharmacological basis of therapeutics Bd. 12. Mc Graw Hill Medical, New York, Chicago, San Francisco Gilman’s G (2011) The pharmacological basis of therapeutics Bd. 12. Mc Graw Hill Medical, New York, Chicago, San Francisco
60.
Zurück zum Zitat Diel I (2012) Kieferosteonekrosen in der Osteoonkologie. Osteolgie 3:194–200 Diel I (2012) Kieferosteonekrosen in der Osteoonkologie. Osteolgie 3:194–200
Metadaten
Titel
Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?
Gesamtauswertung des Deutschen Kieferosteonekroseregisters
verfasst von
BA Cand. med. Dent. Niels Karberg
Prof. Dr. med. Dieter Felsenberg
Publikationsdatum
10.01.2020
Verlag
Springer Vienna
Erschienen in
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen / Ausgabe 1/2020
Print ISSN: 2412-8260
Elektronische ISSN: 2412-8287
DOI
https://doi.org/10.1007/s41970-019-00094-6

Weitere Artikel der Ausgabe 1/2020

Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen 1/2020 Zur Ausgabe

Mitteilungen des Magnesiumforum Bad Radkersburg

Mitteilungen des Magnesiumforum Bad Radkersburg

Mitteilungen der ÖGKM

Mitteilungen der ÖGKM

News-Screen Rheumatologie

News-Screen Rheumatologie